Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property

Reuters

Mar 03, 2025

March 3 (Reuters) - QIAGEN NV ::
*TAKES LEGAL ACTION TO DEFEND QUANTIFERON INTELLECTUAL PROPERTY AND PROTECT INNOVATIONS IN LATENT TUBERCULOSIS TESTING
*COMPLAINT, FILED IN LOCAL DIVISION OF COURT OF FIRST INSTANCE OF UNIFIED PATENT COURT $(UPC)$ IN DUESSELDORF, GERMANY, CONCERNS EUROPEAN PATENT EP 2 276 883 B2
*FILES LAWSUIT AGAINST BIOMÉRIEUX WITH GERMAN UNIFIED PATENT COURT TO PROTECT KEY INNOVATIONS IN ITS QUANTIFERON TECHNOLOGY

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 03-MAR-202506:00:00.247 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516577992"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516577992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516577992?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-03 14:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516577992","market":"nz","top_or_hot":-1,"title":"Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property","media":"Reuters","content":"<html><body>March 3 (Reuters) - QIAGEN NV <qia.de>::<br/>*TAKES LEGAL ACTION TO DEFEND QUANTIFERON INTELLECTUAL PROPERTY AND PROTECT INNOVATIONS IN LATENT TUBERCULOSIS TESTING<br/>*COMPLAINT, FILED IN LOCAL DIVISION OF COURT OF FIRST INSTANCE OF UNIFIED PATENT COURT <a href=\"https://laohu8.com/S/UPC\">$(UPC)$</a> IN DUESSELDORF, GERMANY, CONCERNS EUROPEAN PATENT EP 2 276 883 B2<br/>*FILES LAWSUIT AGAINST BIOMÉRIEUX WITH GERMAN UNIFIED PATENT COURT TO PROTECT KEY INNOVATIONS IN ITS QUANTIFERON TECHNOLOGY<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 03-MAR-202506:00:00.247 GMT</qia.de></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQiagen Takes Legal Action To Defend Quantiferon Intellectual Property\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-03 14:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>March 3 (Reuters) - QIAGEN NV <qia.de>::<br/>*TAKES LEGAL ACTION TO DEFEND QUANTIFERON INTELLECTUAL PROPERTY AND PROTECT INNOVATIONS IN LATENT TUBERCULOSIS TESTING<br/>*COMPLAINT, FILED IN LOCAL DIVISION OF COURT OF FIRST INSTANCE OF UNIFIED PATENT COURT <a href=\"https://laohu8.com/S/UPC\">$(UPC)$</a> IN DUESSELDORF, GERMANY, CONCERNS EUROPEAN PATENT EP 2 276 883 B2<br/>*FILES LAWSUIT AGAINST BIOMÉRIEUX WITH GERMAN UNIFIED PATENT COURT TO PROTECT KEY INNOVATIONS IN ITS QUANTIFERON TECHNOLOGY<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 03-MAR-202506:00:00.247 GMT</qia.de></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QGEN","symbol_name":"快而精医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nRSDJ5sTF:1","article_id":"2516577992","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516577992","pubTimestamp":1740982536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"March 3 (Reuters) - QIAGEN NV ::*TAKES LEGAL ACTION TO DEFEND QUANTIFERON INTELLECTUAL PROPERTY AND PROTECT INNOVATIONS IN LATENT TUBERCULOSIS TESTING*COMPLAINT, FILED IN LOCAL DIVISION OF COURT OF FI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4121":"生命科学工具和服务","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD"},"translate_title":"Qiagen采取法律行动捍卫Quantiferon知识产权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"March 3 (Reuters) - QIAGEN NV ::*TAKES LEGAL ACTION TO DEFEND QUANTIFERON INTELLECTUAL PROPERTY AND PROTECT INNOVATIONS IN LATENT TUBERCULOSIS TESTING*COMPLAINT, FILED IN LOCAL DIVISION OF COURT OF FIRST INSTANCE OF UNIFIED PATENT COURT $(UPC)$ IN DUESSELDORF, GERMANY, CONCERNS EUROPEAN PATENT EP 2 276 883 B2*FILES LAWSUIT AGAINST BIOMÉRIEUX WITH GERMAN UNIFIED PATENT COURT TO PROTECT KEY INNOVATIONS IN ITS QUANTIFERON TECHNOLOGY  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-MAR-202506:00:00.247 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}